[{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,800.0 million","upfrontCash":"$2,800.0 million","newsHeadline":"Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"BeiGene","amount2":2.7999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":2.7999999999999998,"dosageForm":"Injection","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ Amgen"},{"orgOrder":0,"company":"Betagenon","sponsor":"Ivy Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"China-Based Ivy Capital Invests in Betagenon\\'s Clinical Stage AMPK Activator Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"O304","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Betagenon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betagenon \/ Ivy Capital","highestDevelopmentStatusID":"8","companyTruncated":"Betagenon \/ Ivy Capital"},{"orgOrder":0,"company":"Ro","sponsor":"Greenstone LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer\u2019s Greenstone and Digital Men\u2019s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra\u00ae (sildenafil citrate)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ro","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ro \/ Greenstone","highestDevelopmentStatusID":"12","companyTruncated":"Ro \/ Greenstone"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProtoKinetix Takes Delivery of GMP AAGP\u00ae PKX-001 Dedicated for Phase 1 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PKX-001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Positive Phase I Study Results of Oral Octreotide using RaniPill\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"SSTR","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"$67.1 million","upfrontCash":"$5.1 million","newsHeadline":"VALBIOTIS inks Strategic Partnership With NESTL\u00c9 HEALTH SCIENCE","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"TOTUM-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0.070000000000000007,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Science","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Science"},{"orgOrder":0,"company":"MRM Health","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","amount":"$15.1 million","upfrontCash":"Undisclosed","newsHeadline":"DuPont Nutrition & Biosciences Enters into Collaboration","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Gut microbiome based therapeutics","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"MRM Health","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"MRM Health \/ DuPont","highestDevelopmentStatusID":"1","companyTruncated":"MRM Health \/ DuPont"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Protein Sciences Corporation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Diamyd enters agreement to facilitate transition of manufacturing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Diamyd","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Protein Sciences Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Medical AB \/ Protein Sciences Corporation"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ National Securities Corporation"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Receives FDA Breakthrough Therapy for Apabetalone","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Unveils Results from Simplici-T1 Study of TTP399","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Regulatory Path Forward for TLANDO\u2122 Resubmission","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Announces First Participant Trial of Wholly-Owned Lymphedema LYT-100","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Not Applicable "},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Altamira Therapeutics \/ Not Applicable "},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable "},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable "},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"JDRF T1D","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ JDRF T1D","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire Immune Medicines \/ JDRF T1D"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$3.5 million","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi\u00ae Sprinkle","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diurnal Group","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Evotec","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Ildong to collaborate with development projects on INDiGO platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"IDG-16177","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Ildong","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Ildong"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProtoKinetix Ready to Ship AAGP\u00ae to the University of Alberta for the Continuation of Phase 1 Human Trials","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Submits New Drug Application for ISTURISA\u00ae in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Not Applicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Provides COVID-19 Business Update","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Announces Positive Results In Dose-Finding Pediatric Study Of Macimorelin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Macimorelin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Zentaris \/ Not Applicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Napo EU","sponsor":"Atlas Sciences","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NP-500","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Napo EU \/ Atlas Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Atlas Sciences"},{"orgOrder":0,"company":"Delpharm Group","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Delpharm Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Delpharm Group \/ AzurRx BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Delpharm Group \/ AzurRx BioPharma"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Orphan Drug Designation for TransCon\u2122 hGH as Treatment for Growth Hormone Deficiency in the US","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Poxel \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon\u2122 PTH","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical receives Japanese patent for intralymphatic administration of diabetes vaccine Diamyd","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"rhGAD65","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hua Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hua Medicine \/ Not Applicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health to Present Somatrogon Phase 3 Pediatric Trial Results at ENDO Online 2020","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Health \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strongbridge Biopharma plc Announces Completion of Enrollment of Phase 3 LOGICS Study for RECORLEV for Endogenous Cushing\u2019s Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Creapharm","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Enters into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Trial Drug Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Creapharm","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Creapharm \/ AzurRx","highestDevelopmentStatusID":"8","companyTruncated":"Creapharm \/ AzurRx"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Strongbridge Biopharma plc Announces $30 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-101","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Shares Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces FDA Acceptance of NDA for the Dasiglucagon Hypopal rescue Pen for Treatment of Severe Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Sernova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and Sernova to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Recombinant pluripotent stem cell-derived pancreatic islet beta cells","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ Sernova","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Therapeutics \/ Sernova"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"saRNA","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Mina Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$7.0 million","newsHeadline":"REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV\u00ae Technology Platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Gene Therapy-AAV8","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenxbio \/ Ultragenyx","highestDevelopmentStatusID":"1","companyTruncated":"Regenxbio \/ Ultragenyx"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"QVT","pharmaFlowCategory":"D","amount":"$80.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kriya Therapeutics announces $80 million Series A financing to advance gene therapies for highly prevalent serious diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"KT-A112","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Kriya Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Kriya Therapeutics \/ QVT","highestDevelopmentStatusID":"1","companyTruncated":"Kriya Therapeutics \/ QVT"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk To Present New Data at the 80th Annual American Diabetes Association Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases Announces First European Launch of Isturisa\u00ae (osilodrostat)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Alize\u0301 Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alize Pharma 3 Announces Rebranding to Amolyt Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Alize\u0301 Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alize\u0301 Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alize\u0301 Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"$278.0 million","upfrontCash":"$266.0 million","newsHeadline":"Takeda to Divest Select APAC Assets to Celltrion for $278M","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Celltrion","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Celltrion"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Participation in ENDO Online 2020","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Not Applicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health Announces Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Health \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor announces oral presentation of the first phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lannett Company, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Starts Large-Scale Trial of Tirzepatide In Diabetic Heart Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Trial for Paltusotine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational, Once-Weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-Daily Insulin Glargine U100 In Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Presents Clinical and Non-Clinical Evidence for Dasiglucagon Rescue Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Presents Data on Simplici-T1 Study Supporting the Role of TTP399 as an Oral Adjunctive Therapy for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Domp\u00e9 Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ladarixin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Micro\u2122 Glucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Diasome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diasome Reports Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diasome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diasome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Diasome Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ManKind Presents Positive Original Analyses of Afrezza\u00ae Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$95.7 million","upfrontCash":"Undisclosed","newsHeadline":"Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ SVB Leerink"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases: Isturisa\u00ae (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing\u2019s Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Pfizer\u2019s Steglatrotm Meets Primary Endpoint in VERTIS CV Trial for Type 2 Diabetes and Atherosclerotic Cardiovascular Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ertugliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of XP-3924 in Adults with Type 1 DM","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pramlintide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces Pre-Clinical Data on GL0034 to Treat Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GL0034","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces First Patient Dosed in Phase 2 Trial With Long-Acting GLP-1\/Glucagon Dual Agonist in Obesity\/Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 456906","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ImmunoMolecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IM Therapeutics Announces First Patient Dosed in Ph1 Study IMT-002","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IMT-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ImmunoMolecular Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoMolecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMolecular Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Submission of Biologics License Application for TransCon\u2122 hGH in Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0.070000000000000007,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ Jefferies"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV for Endogenous Cushing\u2019s Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Positive Opinion from the Paediatric Committee of the EMA on the Agreement of a Paediatric Investigation Plan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rybelsus\u00ae approved in Japan for the treatment of type 2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProLynx announces SBIR Arant Award to Develop Long-Ating Parathyroid Hormone for Hypo-Parathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"PTH(1-34)","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProLynx \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ National Institute of Health"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Center Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CS02 Changes the Landscape of Diabetes Treatment: CenterLab Announces Positive Topline Results of Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CS02","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Center Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Center Laboratories \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Center Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amendments to ProtoKinetix AAGP\u00ae Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All Patients Have Completed their 15-month Visits in the European Phase IIb Trial with the Diabetes Vaccine Diamyd","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camargo Client Chiasma Receives FDA Approval for Novel Somatostatin Analog for Long-Term Maintenance Treatment of Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ Not Applicable"},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"NIH Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"University of Pittsburgh \/ National Institutes of Health"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$34.6 million","upfrontCash":"Undisclosed","newsHeadline":"MBX Debuts with $35M to Bankroll Rare Endocrine Pipeline","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosciences \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies In Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Cediprof","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett and Cediprof Announce Exclusive Distribution Agreement for An Approved Levothyroxine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lannett Company, Inc. \/ Cediprof","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Cediprof"},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PreveCeutical Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeutical Medical \/ Not Applicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Announces the First Patient Visit in the International Phase II\/III REVERSE-IT Clinical Study on TOTUM-63","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Totum-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Not Applicable"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$33.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Raises \u20ac28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and IBD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Pharmaceuticals \/ Sofinnova Partners"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adalvo and AmbioPharm Partner on Development & Licensing for Key Peptide Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","da
Market Place